Benzinga · Oct 19, 2026
HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Crescent Biopharma (NASDAQ:CBIO) with a Buy and maintains $36 price target.
CB
NASDAQ · CBIO
Crescent Biopharma, Inc. Common Stock
Healthcare · Biotechnology
$13.48
Down-$0.59 (-4.19%)
Updated Oct 31, 2026, 7:11 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 213.67M
- P/E ratio
- -45.46
- Dividend yield
- 0.00%
- 52-week range
- $8.72 – $27.41
- Volume
- 189.52K
- Avg. volume
- 143.92K
Price performance · CBIO
CBIO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
CBIO closed at $13.48 after 21 trading sessions, down 5.87% for the selected period.
- Last close
- $13.48
- Period change
- -5.87%
- Period low
- $11.84
- Period high
- $14.91
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $13.94 | $14.565 | $13.31 | $13.48 | 189.52K |
| Oct 29, 2026 | $13.66 | $14.94 | $13.555 | $14.07 | 378.02K |
| Oct 28, 2026 | $13.27 | $13.635 | $12.75 | $13.50 | 238.74K |
| Oct 27, 2026 | $12.81 | $13.47 | $12.56 | $13.27 | 288.23K |
| Oct 26, 2026 | $12.87 | $13.27 | $12.50 | $12.76 | 210.64K |
| Oct 23, 2026 | $13.36 | $13.36 | $12.62 | $12.82 | 397.81K |
| Oct 22, 2026 | $13.05 | $13.67 | $12.89 | $13.14 | 164.13K |
| Oct 21, 2026 | $13.16 | $13.81 | $13.12 | $13.17 | 250.37K |
| Oct 20, 2026 | $12.40 | $13.63 | $12.40 | $13.07 | 299.61K |
| Oct 19, 2026 | $11.91 | $12.94 | $11.82 | $12.36 | 230.69K |
| Oct 16, 2026 | $12.73 | $12.73 | $11.78 | $11.84 | 208.18K |
| Oct 15, 2026 | $12.62 | $13.19 | $12.31 | $12.48 | 295.94K |
| Oct 14, 2026 | $12.67 | $13.2099 | $12.18 | $12.58 | 284.78K |
| Oct 13, 2026 | $14.46 | $14.67 | $12.85 | $12.91 | 197.11K |
| Oct 12, 2026 | $14.79 | $15.09 | $14.32 | $14.46 | 153.9K |
| Oct 9, 2026 | $14.07 | $15.28 | $14.07 | $14.91 | 347.15K |
| Oct 8, 2026 | $13.39 | $14.61 | $12.98 | $14.12 | 301.26K |
| Oct 7, 2026 | $13.47 | $14.20 | $13.265 | $13.49 | 1.05M |
| Oct 6, 2026 | $14.78 | $14.9291 | $13.455 | $13.57 | 492.37K |
| Oct 5, 2026 | $14.42 | $14.42 | $13.63 | $13.94 | 187.01K |
| Oct 2, 2026 | $14.48 | $14.55 | $14.07 | $14.32 | 283.27K |
Latest CBIO news
The latest Smart Investors Daily articles mentioning CBIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CBIO research
Overview
Company profile and research snapshot.
Company profile
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $29.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 6, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 14, 2026 | Wedbush | Outperform | — |
| Aug 27, 2026 | Wedbush | Outperform | — |
| Jun 1, 2026 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 15, 2026
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001 plus standard of care chemotherapy combinations from ASCEND expansion cohorts in several solid tumor types in treatment-naive and previously treated patients, including first-line NSCLC, colorectal, bi
Benzinga · Oct 15, 2026
Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027
Global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027Phase 1/2 trial of CR-003 (SKB105), an ITGB6-targeted ADC, ongoing in
Benzinga · Oct 6, 2026
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
